ssgj-613
mAbexperimental
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
3
Phase 3
1
Phase 4
0
Earliest trial started Aug 13, 2021 (NCT05027373)
Timeline
Indications
Mechanism of action
- Interleukin-1 betaANTAGONIST
IL1B
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06270225 | Phase 2 | Mar 30, 2024 | Sunshine Lake Pharma Co., Ltd. |
| NCT06169891 | Phase 3 | Dec 31, 2023 | Fudan University, Sunshine Lake Pharma Co., Ltd. |
| NCT05966701 | Phase 1 | Aug 10, 2023 | Shanghai Xuhui District Central Hospital, Sunshine Lake Pharma Co., Ltd. |
| NCT05588908 | Phase 1/Phase 2 (Phase 2) | Jun 29, 2022 | Fudan University, Sunshine Lake Pharma Co., Ltd. |
| NCT05027373 | Phase 1 | Aug 13, 2021 | Sunshine Lake Pharma Co., Ltd. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Sunshine Lake Pharma Co., Ltd. | For profit | 5 | 5 | 3 | 2021 |
| Fudan University | Academic/Hospital | 2 | 0 | 2 | 2022 |
| Shanghai Xuhui District Central Hospital | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1